semaglutide

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that...

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1...

Hims & Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant. Check out the current price of HIMS...

Novo Nordisk A/S (NYSE:NVO) is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide and cagrilintide and aims to reduce weight by 25% without added side effects. What Happened: The Danish pharmaceutical giant is contending with rivals like Eli Lilly & Co...

Novo Nordisk (NYSE:NVO) has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of its drugs Wegovy and Ozempic by compounding pharmacies. These cheaper alternatives have been under scrutiny due to potential safety risks and lack of FDA approval....

Criminals are distributing fake versions of the weight-loss drug Ozempic by forging the drug batch numbers pharmaceutical companies use to authenticate drugs and track them in a specified country. They obtain batch numbers illicitly through a liaison who works at a drugmaker factory or by buying...

The recently launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). These two companies are at the forefront of the burgeoning...

Tema, the exchange-traded fund platform, has launched a healthcare ETF focused on companies that research and treat cardiovascular disease and conditions associated with obesity and diabetes, including Novo Nordisk, maker of the blockbuster diet drug Ozempic. The Tema Cardiovascular and Metabolics...

The year 2023 has had its share of themes and innovations, but perhaps none have been as impactful as the rise of artificial intelligence. The choice of “AI” as the word of the year by a leading dictionary is unsurprising to many, given its enduring relevance. What Happened: Much like...

Danish pharma giant Novo Nordisk A/S (NYSE:NVO) reported a strong increase in first-half sales and profits and also hiked its guidance for the full year for the second time this year. What Happened: Novo Nordisk said its net sales for the first half of the year climbed 29% year-over-year to 107.67...

The demand for the weight-loss drug semaglutide, used by celebrities like Elon Musk and Jeremy Clarkson, is causing a national shortage in the U.K., putting the lives of diabetics at risk, The Daily Mail reports. Off-Label Prescribing Fuels Shortage: The drug, marketed as Ozempic and used for...

Actress Raven-Symoné has voiced her concerns about the misuse of the Type 2 diabetes drug Ozempic for weight loss purposes in Hollywood, PopCulture reports. “I think it’s very important we understand certain medications are made for certain people and to not take that away just for...

Novo Nordisk (NYSE:NVO), the pharmaceutical giant behind popular semaglutide drugs like Ozempic, Rybelsus, and Wegovy, is making a significant legal push to prevent the sale of semaglutide knockoffs in the U.S., Rolling Stone reports. Legal Battle Against Knockoffs According to the lawsuits...

Jessica Simpson has refuted rumors suggesting that her significant weight loss was due to the controversial diabetes drug, Ozempic, NZ Herald reports. Denial of Ozempic Use In an interview with Bustle, Simpson denied using Ozempic, a drug known for its weight loss-inducing tendencies and popularity...

Jessica Simpson has refuted rumors suggesting that her significant weight loss was due to the controversial diabetes drug, Ozempic, NZ Herald reports. Denial of Ozempic Use In an interview with Bustle, Simpson denied using Ozempic, a drug known for its weight loss-inducing tendencies and popularity...